Antimicrobial peptides are among the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori
Section snippets
Background
Helicobacter pylori is a specific inhabitant of the human stomach present in 70–90% of the population in developing countries and in 25–50% in developed countries [1]. The integrants of this species constitute a highly plastic population that can subsist in dynamic equilibrium with the host without causing infection. However, their ability to adapt to host-specific constraints represents an increasing health risk [2]. Currently, they are considered to be the most important aetiological agent of
Bacterial strains, isolation and growth conditions
The reference bacterial strains included in this study were: Helicobacter pylori NCTC 11638, Helicobacter pylori NCTC 11637, Campylobacter coli NCTC 11366, Listeria innocua ATCC 33090 and Lactococcus lactis MG1363 [11].
Helicobacter pylori from gastric biopsies were cultured by streak plating with a 10 μl plastic sterile loop on Pylori Agar (BioMerieux, France) and on Columbia agar Base (Difco, USA) with 7% (v/v) laked horse blood and Helicobacter selective supplement (SR147E, Oxoid, England).
Isolation and identification
In order to select only acid-resistant strains of the genus Bifidobacterium, faecal samples were initially pre-incubated in MRS-C, at pH 2.0. A total of 60 presumptive Bifidobacterium strains were isolated, whose identity was determined by PCR using genus-specific primers. In every case, a 1.35 kb 16S rDNA fragment was detected confirming the correct assignation of the isolates to the genus Bifidobacterium (data not shown). Finally, RAPD-PCR analysis distinguished 24 different strains (data not
Discussion
In recent years, the number of cases of H. pylori infections has increased worldwide and so has the development of strains highly resistant to commonly used antibiotics [2]. This pathogen is becoming a clinical and therapeutic problem as such infections are largely controlled by antibiotics, which may no longer constitute a satisfactory therapy. In this sense, the use of probiotics, which could interfere with the colonization of bacterial pathogens, is one of the promising alternative or
Acknowledgements
This work has been supported by Grants GV04B/590 from Consellería de Cultura y Educación de la Generaltitat Valenciana (Spain) and AGL2002-04480-C03-03 from Ministerio de Ciencia y Tecnología (Spain). FPU/MEC (Spain) scholarships to M.C. Collado and A. González are fully acknowledged.
References (23)
Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model
Gastroenterology
(1997)The role of probiotics in the treatment and prevention of Helicobacter pylori infection
Int J Antimicrob Agents
(2003)- et al.
Characterization and antimicrobial spectrum of Bifidocin B, a bacteriocin produced by Bifidobacterium bifidum NCFB 1454
J Food Prot
(1998) - et al.
Probiotics and Helicobacter pylori
Best Pract Res Clin Gastroenterol
(2003) - et al.
Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model
Am J Gastroenterol
(1998) - et al.
Antagonism of Helicobacter pylori by bacteriocins of lactic acid bacteria
J Food Prot
(2003) Natural history and epidemiology of Helicobacter pylori infection
Aliment Pharm Ther
(2002)- et al.
Helicobacter pylori persistence: biology and disease
J Clin Invest
(2004) - et al.
Appearance of metronidazole-resistant Helicobacter pylori strain in an Infected-ICR-mouse model and difference in eradication of metronidazole-resistant and -sensitive strains
Antimicrob Agents Chemother
(1997) Community acquired acute Helicobacter pylori gastritis
J Gastroenterol Hepatol
(2000)
Probiotics: an overview of beneficial effects
Antonie van Leeuwenhoek
Cited by (88)
Bacteria producing antimicrobials against Clostridium difficile isolated from human stool
2020, AnaerobeCitation Excerpt :This may suggest that the antimicrobial effect of our two isolates is not due to mainly antimicrobial peptide production. But this may not also exclude entirely the presence of proteinaceous substances as noticed in a study by Ref. [21] that the inhibitory activity of CFSs from the selected Bifidobacteria was destroyed by all tested proteases except for proteinase K, which also exerted an inhibitory effect on H. pylori. This was explained by the possible generation of additional antimicrobial peptides form proteins present in CFSs by proteinase K.
The gut microbiome
2019, Effects of Lifestyle on Men’s HealthInteractions between host and microbiota
2018, Medicine (Spain)Understanding the role of gut microfloral bifidobacterium in cancer and its potential therapeutic applications
2024, Microbiome Research Reports